Document is current

Article History

Received: 5 September 2020

Revised: 27 October 2020

Accepted: 5 November 2020

First Online: 1 February 2021

<!--Emphasis Type='Bold' removed-->Competing interests

: A.M. received research funding from Celgene Corporation. C.D.D. reports personal fees from Abbvie, Agios, Novartis, ImmuneOnc, Daiichi-Sankyo, Celgene, Jazz, and Notable Labs, outside the submitted work. N.G.D. reports grants from Abbvie, Genentech, Astellas, Daiichi-Sankyo, Pfizer, BMS, Immunogen, Novimmune, Forty Seven, Inc., personal fees from Abbvie, Genentech, Astellas, Daiichi-Sankyo, Pfizer, BMS, Immunogen, Jazz Pharmaceuticals, Trillium, Forty Seven, Inc., Gilead, Kite, and Novartis. C.R.R.: none. F.R. received personal fees and research grants from Abbvie. N.P. reports personal fees from Pacylex Pharmaceuticals, Incyte, LFB Biotechnologies, Roche Diagnostics, and Blueprint Medicines, grants and other from Affymetrix, grants from SagerStrong Foundation, personal fees and other from Novartis, personal fees, nonfinancial support, and other from Stemline Therapeutics and AbbVie, personal fees and nonfinancial support from Celgene, MustangBio, and DAVA Oncology, and other from Samus Therapeutics, Cellectis, Daiichi-Sankyo, and Plexxikon, outside the submitted work. G.B.: research funding—AbbVie, Incyte, Janssen, GSK, and Cyclacel; consultancy and research funding—BioLine Rx; consultancy—NKarta and PTC Therapeutics; research funding—Oncoceutics, Inc. M.O. and G.M.B: none. N.J.S. reports grants from Takeda Oncology and Astellas; personal fees from Takeda Oncology, AstraZeneca, and Amgen. Y.A. and T.M.K.: none. K.T. has received personal fees for service on the advisory boards of Symbio Pharmaceuticals, GSK, and Celgene. M.Y.: none. N.J.: consultancy, honoraria, membership on an entity’s Board of Directors or advisory committees, and research funding—AbbVie, Pharmacyclics, an AbbVie company, Janssen Pharmaceuticals, Inc., Genentech, Pfizer, ADC Therapeutics, AstraZeneca, Servier, Verastem, Precision Biosciences, and Adaptive Biotechnologies; research funding—BMS, Incyte, and Cellectis. P.B. reports research grant and personal fees from Incyte, Celgene, CTI Biopharma, Kartos Therapeutics, and BluePrint Medicines, and research grants from Constellation Pharmaceuticals, NS Pharma, Promedior, Pfizer, and Astellas. A.F.: none. G.C.I. received research funding from Celgene and served on an advisory board for Novartis. E.J.J.: consultancy research funding from Takeda, BMS, Adaptive, Amgen, AbbVie, Pfizer, and Cyclacel LTD; research grants with Amgen, Abbvie, Spectrum, BMS, Takeda, Pfizer, and Adaptive. P.A.T. reports research funding to the institution and consultancy/honorarium paid to the institution from Pharmacyclics, Abbvie, and Amgen; consultancy/honorarium paid to the institution from Genentech, Gilead Scienes, and Janssen-Cilag; research funding to the institution from Pfizer. K.S.M., S.A.P., and W.G.W.: none. H.M.K.: grants and other from AbbVie, Agios, Amgen, Immunogen, and Pfizer; grants from Ariad, Astex, BMS, Cyclacel, Daiichi-Sankyo, Jazz Pharma, Novartis, Actinium, and Takeda, outside the submitted work. M.Y.K. has received grants from NIH, NCI, Abbvie, Genentech, Stemline Therapeutics, Forty Seven, Inc., Eli Lilly, Cellectis, Calithera, Ablynx, and AstraZeneca; consulting/honorarium from AbbVie, Genentech, F. Hoffman La-Roche, Stemline Therapeutics, Amgen, Forty Seven, Inc., and Kisoji; clinical trial support from Ascentage; stocks/royalties in Reata Pharmaceutical.